SNN / Oxford Biomedica, Smith & Nephew 'vulnerable' to takeover

JPMorgan has upgraded the firm to overweight from neutral pointing out shares have de-rated to 10-year lows in recent weeks. This reflected concerns o more_horizontal

Shares in Smith & Nephew PLC (LSE:SN) surged by 4.2% as the company projected sales growth to hit the upper end of its guidance following a robust thi more_horizontal

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Neverthe more_horizontal

Smith & Nephew (SNN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with s more_horizontal

Smith & Nephew plc (NYSE:SNN ) Q2 2023 Earnings Conference Call August 3, 2023 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer A more_horizontal

Smith & Nephew PLC (LSE:SN) reported improved revenue, profit and margin in the first half making progress towards achieving sustainable higher growth more_horizontal

Smith & Nephew plc is a long-standing company in the medical device sector, focusing on developing and manufacturing internationally. The company has more_horizontal

Smith & Nephew PLC (LSE:SN) held full-year guidance as it reported strong growth in its Sports Medicine and Advanced Wound Management businesses had u more_horizontal